ArticleAmerican journal of translational research2025
Establishment and validation of a prognostic model for controlling adolescents' myopia progression through repeated low-level red-light therapy.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeRepeated low-level red-light (RLRL) therapy has emerged as a possible intervention to control myopia progression. This study aimed to establish and validate a prognostic model for controlling adolescents' myopia progression with RLRL therapy, considering demographic, lifestyle, and ophthalmic parameters.
methodsA retrospective cohort study was conducted on adolescent myopic patients admitted to Cangzhou Central Hospital from January 2022 to June 2023. Patients were divided into a control group and an RLRL treatment group based on their treatment method. Various demographic, lifestyle, and ophthalmic parameters were assessed to identify predictors for treatment response. A comprehensive evaluation using logistic regression and nomogram analysis was performed to identify significant factors associated with treatment outcomes.
resultsThe study included a total of 145 patients, comprising 82 in the control group and 63 in the RLRL group. RLRL therapy demonstrated significantly better effectiveness in controlling myopia progression, with a reduction of -0.62 ± 0.24 D in the RLRL group compared to -0.75 ± 0.36 D in the control group (P=0.010). Furthermore, the RLRL group exhibited improved visual acuity (logMAR) of 0.12 ± 0.06 compared to 0.15 ± 0.07 in the control group (P=0.015). Moreover, baseline demographic and ophthalmic characteristics showed significant associations with treatment outcome, emphasizing the multifaceted nature of myopia response to RLRL therapy. The nomogram analysis demonstrated high predictive performance, with an AUC of 0.994.
conclusionThis study demonstrates the effectiveness and safety of RLRL therapy in controlling myopia progression among adolescents. The establishment of a prognostic model incorporating demographic, lifestyle, and ophthalmic factors offer a promising approach for predicting treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.